Needham & Company LLC reaffirmed their buy rating on shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) in a research report report published on Thursday, The Fly reports. Needham & Company LLC currently has a $32.00 price target on the stock, up from their previous price target of $29.00.
Separately, Zacks Investment Research lowered ZEALAND PHARMA/S from a buy rating to a hold rating in a research note on Saturday, July 27th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. ZEALAND PHARMA/S has a consensus rating of Buy and a consensus price target of $27.00.
NASDAQ ZEAL opened at $21.15 on Thursday. The stock has a 50-day simple moving average of $22.16 and a two-hundred day simple moving average of $19.19. The firm has a market capitalization of $669.62 million, a P/E ratio of 7.05 and a beta of 1.91. ZEALAND PHARMA/S has a fifty-two week low of $11.51 and a fifty-two week high of $23.55.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.10). The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $7.50 million. Sell-side analysts expect that ZEALAND PHARMA/S will post -2.1 earnings per share for the current year.
A hedge fund recently raised its stake in ZEALAND PHARMA/S stock. Farallon Capital Management LLC raised its stake in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) by 5.4% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 1,000,000 shares of the company’s stock after buying an additional 51,300 shares during the period. Farallon Capital Management LLC owned about 3.25% of ZEALAND PHARMA/S worth $21,550,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.08% of the company’s stock.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Featured Story: What is a Real Estate Investment Trust (REIT)?
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.